Quantum Biopharma Ltd. (QNTM) — SEC Filings
Quantum Biopharma Ltd. (QNTM) — 50 SEC filings. Latest: 6-K (May 7, 2026). Includes 49 6-K, 1 20-F.
View Quantum Biopharma Ltd. on SEC EDGAR
Overview
Quantum Biopharma Ltd. (QNTM) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 2, 2026: Quantum Biopharma Ltd. filed a Form 6-K on April 2, 2026, reporting information as a foreign issuer. The filing includes a press release as Exhibit 99.1. The company's mailing and business address is 55 University Avenue, Suite 1003, Toronto, Ontario, Canada.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 49 neutral, 1 mixed. The dominant filing sentiment for Quantum Biopharma Ltd. is neutral.
Filing Type Overview
Quantum Biopharma Ltd. (QNTM) has filed 49 6-K, 1 20-F with the SEC between May 2025 to May 2026.
Filings by Year
Recent SEC Filings (50)
| Date | Form | Description | Risk |
|---|---|---|---|
| May 7, 2026 | 6-K | 6-K Filing | |
| Apr 2, 2026 | 6-K | Quantum Biopharma Files 6-K Report | low |
| Apr 1, 2026 | 6-K | Quantum Biopharma Ltd. Files 6-K Report | low |
| Mar 30, 2026 | 6-K | Quantum Biopharma Files 6-K Report | low |
| Mar 27, 2026 | 6-K | Quantum Biopharma Files 6-K Report | low |
| Mar 26, 2026 | 20-F | Quantum Biopharma Eyes Phase 2 for MS Drug, Consolidates Shares | high |
| Mar 26, 2026 | 6-K | Quantum Biopharma Files Routine 6-K Report on March 26, 2026 | |
| Dec 23, 2025 | 6-K | 6-K Filing | |
| Dec 22, 2025 | 6-K | Quantum Biopharma Ltd. Files December 2025 6-K Report | low |
| Dec 22, 2025 | 6-K | 6-K Filing | |
| Dec 8, 2025 | 6-K | 6-K Filing | |
| Dec 1, 2025 | 6-K | 6-K Filing | |
| Nov 28, 2025 | 6-K | Quantum Biopharma Ltd. Files 6-K Report | low |
| Nov 26, 2025 | 6-K | 6-K Filing | |
| Nov 25, 2025 | 6-K | 6-K Filing | |
| Nov 7, 2025 | 6-K | 6-K Filing | |
| Nov 6, 2025 | 6-K | Quantum Biopharma Files 6-K Report | low |
| Nov 3, 2025 | 6-K | 6-K Filing | |
| Oct 29, 2025 | 6-K | Quantum Biopharma Ltd. Files Form 6-K | low |
| Oct 23, 2025 | 6-K | Quantum Biopharma Ltd. Files October 2025 6-K Report | low |
Risk Profile
Risk Assessment: Of QNTM's 40 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 39 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Zeeshan Saeed
Industry Context
Quantum Biopharma operates in the highly competitive biopharmaceutical sector, focusing on novel therapeutics for neurological conditions like multiple sclerosis and substance misuse. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight from bodies like the FDA and EMA.
Top Tags
foreign-private-issuer (25) · reporting (16) · regulatory-filing (15) · company-update (13) · sec-filing (11) · foreign-issuer (10) · 6-K (6) · press-release (2) · disclosure (2) · 6-k (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Share Consolidation Ratio | 65:1 | Ratio for Class A Multiple Voting Shares and Class B Subordinate Voting Shares on August 15, 2024 |
| Class A Multiple Voting Shares Outstanding | 42 | As of December 31, 2025, post-consolidation |
| Class B Subordinate Voting Shares Outstanding | 3,887,729 | As of December 31, 2025, post-consolidation |
| Average Exchange Rate | US$1.00 to C$1.3979 | For the 2025 fiscal year, used for Canadian dollar translations |
| Commission File Number | 001-39152 | Identifies the company's SEC filing history |
| Filing Date | 20251029 | Date the 6-K was officially filed |
| Conformed Period of Report | 20240925 | The period the report is intended to cover |
| SEC File Number | 001-39152 | Identifies the company's filing with the SEC |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Quantum Biopharma Ltd. (QNTM)?
Quantum Biopharma Ltd. has 50 recent SEC filings from May 2025 to May 2026, including 49 6-K, 1 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of QNTM filings?
Across 50 filings, the sentiment breakdown is: 49 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Quantum Biopharma Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Quantum Biopharma Ltd. (QNTM) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Quantum Biopharma Ltd.?
Financial highlights for Quantum Biopharma Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for QNTM?
The investment thesis for QNTM includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Quantum Biopharma Ltd.?
Key executives identified across Quantum Biopharma Ltd.'s filings include Zeeshan Saeed.
What are the main risk factors for Quantum Biopharma Ltd. stock?
Of QNTM's 40 assessed filings, 1 were flagged high-risk, 0 medium-risk, and 39 low-risk.
What are recent predictions and forward guidance from Quantum Biopharma Ltd.?
Forward guidance and predictions for Quantum Biopharma Ltd. are extracted from SEC filings as they are enriched.